Stage III low rectal cancer: complete response to mFOLFOX6 plus panitumumab and sphincter-preserving surgery

Patient Info: Anonymized, Male, 50s

Biomarkers: KRAS wild-type

As of March 2014, he was alive without evidence of recurrence 3 months after surgery, after complete pathologic response to neoadjuvant mFOLFOX6 plus panitumumab followed by intersphincteric resection and adjuvant UFT/leucovorin.

PubMed CentralRead more →

Sigmoid colon cancer: complete response after repeated metastatic recurrences and multimodal therapy

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: KRAS/NRAS/BRAF status not reported; CEA elevation used for recurrence monitoring

Metastatic Site: left lung, mediastinal lymph nodes, left adrenal…

By 2011, all metastatic lesions had achieved complete response; nearly 1 year after the last adrenal irradiation, no recurrence had been detected.

PubMed CentralRead more →

Sigmoid colon cancer with later inguinal lymph-node metastasis: surgery, FOLFOX, FOLFIRI, and cetuximab

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: CEA was elevated at diagnosis and recurrence. Metastatic lymph node was CK20 positive/CK7 negative; EGFR mutation status not reported.

Metastatic Site: left inguinal lymph node

Apparently disease-free 8 months after surgical removal of the left inguinal lymph-node metastasis followed by FOLFIRI plus cetuximab.

PubMed CentralRead more →